Sahu N, Jain P, Sahu D, Kaur K, Nagori K, Ajazuddin
McGraw-Hill / Lange Rivera FB et al (2024): Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials
Third-party testing certifications (NSF, USP) offer some assurance, but clinical-grade products should be sourced through qualified healthcare providers
After stopping the test product at the 20th week, all treatment groups showed signs of weight recovery
A 2006 Phase I trial of CJC-1295 reported no serious adverse events across a small number of subjects, but it was a safety study, not an outcomes trial, and there are no large trials showing it does what enthusiasts hope
For BPC-157 the peptide that received the most attention and the first vote of the two-day meeting the evidentiary picture was the most developed of the group, which is not saying much